| Website | ceruleanrx.com |
| Category | BioTech |
| Phone | 617-551-9600 |
| info@Ceruleanrx.com | |
| Employees | |
| Founded | 2006 |
| Description | Nanobiology company |
| TOTAL | $72.7M |
| FUNDING TOTAL | $72.7M |
| Venture Round, 12/06 Polaris Partners | $2M |
| Series A, 5/07 Venrock Polaris Partners Lux Capital | $12.1M |
| Series B, 1/08 Polaris Partners Venrock Lux Capital Bessemer Venture Partners Alexandria Real Estate Equities | $8.1M |
| Series B, 7/09 Polaris Partners Venrock Lux Capital Bessemer Venture Partners | $10M |
| Venture Round, 10/10 | $1.5M |
| Series C, 11/10 Lilly Ventures Polaris Partners Venrock Lux Capital Bessemer Venture Partners | $24M |
| Series D, 12/11 Polaris Partners Venrock Lilly Ventures Lux Capital Bessemer Venture Partners | $15M |
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases.
The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
